Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
A phase 1/2 trial of HH2853 Tablets in peripheral T-cell lymphomas, run by Haihe Biopharma Co., Ltd., now recruiting.
Overview
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma is a phase 1/2 interventional study registered as NCT06909877 by Haihe Biopharma Co., Ltd., with 100 participants planned, started 2022-07-27 and due to reach its primary completion in 2025-10-31. Interventions recorded: HH2853 Tablets.
Similar pages
not linked directly; found by shared links- TrialEvaluate the Safety and Clinical Activity of HH2853
Shares Haihe Biopharma, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Shares Haihe Biopharma and the tag pipeline.
- TrialA Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Shares Haihe Biopharma and the tag pipeline.
- TrialChidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialA Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.